Kezar Life Sciences, Inc.
General ticker "KZR" information:
- Sector: Health Care
- Industry: Biotechnology
- Capitalization: $37.1M (TTM average)
Kezar Life Sciences, Inc. follows the US Stock Market performance with the rate: 39.6%.
Estimated limits based on current volatility of 0.7%: low 7.26$, high 7.37$
Factors to consider:
- Total employees count: 58 (-31.0%) as of 2023
- Top business risk factors: High R&D costs, Key executive dependency, Regulatory and compliance, Market competition, Insufficient funding
- Price in estimated range
Stock Forecast*
* forecast is subjective and experimental, should not be used for any investment decisions
Long term estimates were made for the period from 2025-12-31 to 2027-12-31
- 2025-12-31 to 2026-12-31 estimated range: [3.73$, 11.32$]
- 2026-12-31 to 2027-12-31 estimated range: [2.94$, 9.12$]
Financial Metrics affecting the KZR estimates:
- Positive: with PPE of -0.8 at the end of fiscal year the price was neutral
- Negative: negative Operating income
- Negative: Operating cash flow per share per price, % of -112.06 <= 0.07
- Positive: Investing cash flow per share per price, % of 200.11 > -0.65
- Positive: Inventory ratio change, % of 0 <= 0
- Positive: Interest expense per share per price, % of 0 <= 0.01
- Negative: negative Net income
- Positive: Industry inventory ratio change (median), % of 0 <= 0
- Negative: Industry earnings per price (median), % of -14.62 <= 0
Short-term KZR quotes
Long-term KZR plot with estimates
Financial data
| YTD | 2023-12-31 | 2024-12-31 | 2025-12-31 |
|---|---|---|---|
| Operating Revenue | $7.00MM | $0.00MM | $0.00MM |
| Operating Expenses | $118.42MM | $90.61MM | $52.27MM |
| Operating Income | $-111.42MM | $-90.61MM | $-52.27MM |
| Non-Operating Income | $9.55MM | $6.87MM | $-3.76MM |
| Interest Expense | $1.55MM | $1.59MM | $0.00MM |
| R&D Expense | $85.70MM | $65.74MM | $33.76MM |
| Income(Loss) | $-101.87MM | $-83.74MM | $-56.03MM |
| Profit(Loss)* | $-101.87MM | $-83.74MM | $-56.03MM |
| Stockholders Equity | $187.57MM | $116.92MM | $70.07MM |
| Assets | $221.24MM | $144.68MM | $76.65MM |
| Operating Cash Flow | $-81.64MM | $-74.21MM | $-51.78MM |
| Capital expenditure | $1.81MM | $0.03MM | $0.01MM |
| Investing Cash Flow | $76.05MM | $80.43MM | $92.46MM |
| Financing Cash Flow | $0.64MM | $0.10MM | $-10.59MM |
| Earnings Per Share** | $-1.40 | $-1.15 | $-7.66 |
* Profit(Loss) attributable to entity.
** EPS are Split Adjusted, recent splits may be reflected with a delay.